| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2596 |
| Trial ID | NCT04760132 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax |
| Co-treatment | COVID-19 Vaccine AstraZeneca |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase4 |
| Recruitment status | Recruiting |
| Title | National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines |
| Year | 2021 |
| Country | Denmark |
| Company sponsor | Jens D Lundgren, MD |
| Other ID(s) | ENFORCE |
| Vector information | |||
|
|||
| Cohort1: COMIRNATY | |||||||||
|
|||||||||
| Cohort2: MODERNA BIOTECH | |||||||||
|
|||||||||
| Cohort3: Astra-Zeneca COVID-19 vaccine | |||||||||
|
|||||||||